Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  AUSTRALIAN SECURITIES EXCHANGE LIMITED  >  Cochlear Limited    COH   AU000000COH5

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Cochlear Limited : COH Jury Trial Verdict on USA Patent Infringement Case

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/24/2014 | 03:51am CET
ASX RELEASE 24th January 2014 COCHLEAR LIMITED: JURY TRIAL VERDICT ON USA PATENT INFRINGEMENT CASE

Cochlear Limited, Sydney, 24th January 2014 (ASX:COH) today announced that a jury verdict in the patent infringement lawsuit by the Alfred E. Mann Foundation for Scientific Research ("AMF") and Advanced Bionics LLC ("AB") has been reached.
A jury in the United States District Court in Los Angeles, California found direct, contributory and wilful, but not induced infringement against Cochlear Limited and its USA subsidiary Cochlear Americas and awarded damages of US$131.2 million against Cochlear.
No judgment has been entered based on the verdict as important issues still remain to be decided by the Judge. These decisions may negate some of the findings of the jury and could alter the damages awarded by the jury.
Cochlear believes the facts and the law do not support the jury's findings and will seek to overturn the verdict in post-trial motions with the District Court and, if necessary, through the appeals process.
This lawsuit was disclosed to ASX when it was filed in December 2007. The verdict relates to two (2) United States patents on testing systems and methods for a cochlear implant. The patents were exclusively licenced by AMF to AB which is a competitor to Cochlear.
One of the patents expired in September 2009 and the other expires in March 2014. As a result, the verdict and any following judgment entered against Cochlear will not disrupt Cochlear's business or customers in the United States.
As at the date of this announcement, Cochlear had not accrued any liability in its financial statements for this verdict. In addition, Cochlear has not yet determined the impact, if any, on its financial statements.
Cochlear's Chief Executive Officer and President Dr Chris Roberts said, "We strongly disagree with the jury verdict and will appeal any judgment entered against Cochlear by the Court".
Ends
Company contacts:
Dr Chris Roberts, CEO/President p: + 61 2 9428 6555
Neville Mitchell, CFO
p: + 61 2 9428 6555

Page 1 of 1

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on COCHLEAR LIMITED
03/20 COCHLEAR : Hill earns Graeme Clark Scholarship
03/16 COCHLEAR : Patent Issued for Passive Vibration Cancellation System for Microphon..
03/16 COCHLEAR : Patent Issued for Sound Processing Based on a Confidence Measure (USP..
03/16 COCHLEAR : Patent Issued for Cap for an Implantable Electrical Lead Assembly (US..
03/15 COCHLEAR LIMITED : ex-dividend day for interim dividend
03/10 COCHLEAR : Patent Issued for Sound Processing Using a Masking Model (USPTO 95794..
03/10 Commbank-asx 200 dividends rise on higher profits, cash holdings
03/09 COCHLEAR : Patent Issued for Electromechanical Transducer with Mechanical Advant..
03/02 COCHLEAR : Pledges Support to WHO Call for Action
02/28 COCHLEAR : Hearing loss drives Mercedes native toward prestigious honor
More news
Sector news : Medical Prosthetics
03/22DJMEDTRONIC : Files 8K - Other Events
03/17DJMEDTRONIC : Less-Invasive Treatment Yielded Similar Outcome as Open-Heart Surger..
03/11DJLUXOTTICA : Smart Glasses Get a Fresh Look -- WSJ
03/09DJLUXOTTICA : Eyewear Makers Take a Fresh Look at Smart Glasses
03/09DJLUXOTTICA : Eyewear Makers Rethink Smart Glasses
More sector news : Medical Prosthetics
News from SeekingAlpha
2016 How Do I Manage A Favorite Holding That's Now Overvalued?
2016 Smaller Medtechs In Charge Of Their Own Destiny
2016 The Psychology Of Investing
2016 EWA : Getting In Down Under
2015 Cochlear Should Do Well As Its Target Market Expands
Advertisement
Financials ( AUD)
Sales 2017 1 233 M
EBIT 2017 309 M
Net income 2017 222 M
Debt 2017 56,7 M
Yield 2017 2,08%
P/E ratio 2017 33,58
P/E ratio 2018 29,90
EV / Sales 2017 6,12x
EV / Sales 2018 5,52x
Capitalization 7 485 M
More Financials
Chart COCHLEAR LIMITED
Duration : Period :
Cochlear Limited Technical Analysis Chart | COH | AU000000COH5 | 4-Traders
Full-screen chart
Technical analysis trends COCHLEAR LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 126  AUD
Spread / Average Target -3,7%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Christopher M. Smith President, Chief Executive Officer & Director
Roderick Holliday-Smith Chairman
Dig Howitt Chief Operating Officer
James F. Patrick Chief Scientist & Senior Vice President
Jan Janssen SVP-Clinical, Regulatory, Design & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
COCHLEAR LIMITED8.05%5 735
MEDTRONIC PLC13.72%110 880
STRYKER CORPORATION10.55%49 413
BECTON DICKINSON AND C..10.32%38 870
BAXTER INTERNATIONAL I..16.80%28 068
ESSILOR INTL.4.10%26 361
More Results